Home

Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps.

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic.

On March 19, 2020, Roche confirmed initiation of a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR).

AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum's COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need.

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra®/RoActemra® (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.

Favipiravir flu drug 'clearly effective' in treating COVID-19

According to the multiple news articles the drug favipiravir (sold under the brand name Avigan), developed by Fujifilm Toyama Chemical, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

Understanding how COVID-19 affects children vital to slowing pandemic

Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandemic accurately, limit the disease's spread and ensure the youngest patients get the care they need.

PharmaNews.eu

Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts

Roche response to COVID-19 pandemic

AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

Favipiravir flu drug 'clearly effective' in treating COVID-19

Understanding how COVID-19 affects children vital to slowing pandemic

More Pharma News ...